$3.99
0.041.01%
At close: Nov 13, 4:00 PM EST
$3.99
N/A
After Hours: 4:00 PM EST
Vanda Pharmaceuticals Inc
VNDANASDAQ
Vanda Pharmaceuticals (VNDA) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Oct 28, 2026 | $-0.37 | $-0.69 | 46.4 % |
| Q2 | Aug 5, 2026 | $-1.04 | $-0.57 | -82.5 % |
| Q1 | May 6, 2026 | $-0.82 | $-0.66 | -24.2 % |
| Q4 | Feb 11, 2026 | $-2.39 | $-1.67 | -43.1 % |
Quarterly Revenue (Billions)
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Oct 28, 2026 | $69.82M | $68.47M | 1.96 % |
| Q2 | Aug 5, 2026 | $50.53M | $62.07M | -18.6 % |
| Q1 | May 6, 2026 | $51.72M | $54.74M | -5.52 % |
| Q4 | Feb 11, 2026 | $57.22M | $59.11M | -3.20 % |
Vanda Pharmaceuticals (VNDA) last issued guidance on October 28, 2026 for fiscal year 2026. The company guided revenue in the range of for the period.
Compared to prior guidance, Vanda Pharmaceuticals maintained its revenue forecast from a prior range of $240M - $290M.
Vanda Pharmaceuticals has issued 9 guidance updates between July 31, 2024 and August 5, 2026. During this period, the company raised its outlook 4 times and lowered it 1 time, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.69 | $-0.57 | $-0.66 | $-1.67 |
| Actual | $-0.37 | $-1.04 | $-0.82 | $-2.39 |
| Surprise | +46.4% | -82.5% | -24.2% | -43.1% |
| Revenue | ||||
| Estimate | $68.5M | $62.1M | $54.7M | $59.1M |
| Actual | $69.8M | $50.5M | $51.7M | $57.2M |
| Surprise | +1.96% | -18.6% | -5.52% | -3.20% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.31 | $-0.26 | $-0.23 | $-0.13 |
| Revenue | ||||
| Consensus | $70.0M | $72.0M | — | — |
